Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Hightower

Diagnostic Radiology Visalia, CA Medical Doctor

NPI 1437173325 CMS profile 64373

1700 S Court St Ste F, Visalia, CA 93277

Open in the dashboard

General payments

$7,342

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Hightower of Visalia, CA is reported in the CMS Open Payments database as having received $7,342 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,732 14
2024 General $1,575 15
2023 General $1,365 13
2022 General $570 10
2021 General $272 5
2020 General $175 5
2019 General $1,654 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Hightower
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Daniel Hightower were reported at $1,732. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Daniel Hightower Diagnostic Radiology median Middle half National median
2019 $1,654 $108 $29–$318 $163
2020 $175 $65 $21–$252 $114
2021 $272 $92 $24–$292 $132
2022 $570 $104 $29–$294 $149
2023 $1,365 $110 $29–$337 $160
2024 $1,575 $113 $30–$356 $164
2025 $1,732 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $2,820 5 payments
  2. Hitachi Healthcare Americas Corp. $920 5 payments
  3. Medtronic, Inc. $920 23 payments
  4. Inari Medical, Inc. $354 4 payments
  5. Siemens Medical Solutions USA, Inc. $255 7 payments
  6. Merck Sharp & Dohme Corporation $225 2 payments
  7. Bard Peripheral Vascular, Inc. $219 2 payments
  8. FUJIFILM Medical Systems USA, Inc. $198 1 payment
  9. Shockwave Medical, Inc $168 2 payments
  10. Cook Medical LLC $161 2 payments
  11. Other $1,103 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,473 67 payments
  2. Long term medical supply or device loan $2,789 3 payments
  3. Entertainment $920 5 payments
  4. Travel and Lodging $160 2 payments
Products named General payments · program years 2019–2025
  1. VenaCure 1470 Pro Et $1,829 2 payments
  2. VenaCure 1470 Pro Id $960 1 payment
  3. KYPHON EXPRESS II KYPHOPAK TRAY $378 14 payments
  4. FLOWTRIEVER CATHETER, S $354 4 payments
  5. CT THROMBECTOMY SYSTEM KIT $303 2 payments
  6. STEGLATRO $225 2 payments
  7. OASIS $198 1 payment
  8. SYNCHROMEDII $181 3 payments
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $168 2 payments
  10. VANTA ADAPTIVESTIM $156 1 payment
  11. Other $1,784 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 223 billing codes

Paid by Medicare

$282,214

Of which drugs: $1,909

Medicare patients

3,132

Average age 74

Services billed

22,238

1,711 women, 1,421 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 47%
Ischemic heart disease 42%
Chronic kidney disease 38%
Heart failure 31%
Depression 29%
COPD 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadoterate meglumine, 0.1 ml A9575 Office 52 8,700 $820
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 85 7,853 $774
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 85 418 $315

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record